Sushil K Tripathi1, Pardeep Kumar2, Edouard J Trabulsi3, Sung Kim2, Peter A McCue4, Charles Intenzo2, Adam Berger5, Leonard Gomella6, Mathew L Thakur7. 1. Thomas Jefferson University, Department of Radiology. Electronic address: sushil2718@gmail.com. 2. Thomas Jefferson University, Department of Radiology. 3. Thomas Jefferson University, Department of Urology. 4. Thomas Jefferson University, Department of Pathology. 5. Thomas Jefferson University, Department of Surgery. 6. Thomas Jefferson University, Department of Urology; The Sidney Kimmel Cancer Center. 7. Thomas Jefferson University, Department of Radiology; The Sidney Kimmel Cancer Center. Electronic address: Mathew.Thakur@jefferson.edu.
Abstract
INTRODUCTION: Previously, our laboratory has shown that 64Cu-TP3805 can specifically target VPAC1 receptors and be used for positron emission tomography (PET) imaging of breast (BC) and prostate cancer (PC) in humans. Present work is aimed at the formulation of a freeze-dried diaminedithiol-peptide (N2S2-TP3805) kit and it's evaluation for the preparation of 64Cu labeled TP3805. Parameters such as pH, temperature and incubation time were examined that influenced the radiolabeling efficiency and stability of the product. METHODS: Kits were prepared under different conditions and radiolabeling efficiency of TP3805 kit was evaluated for a range of pH3.5-8.5, after addition of 64Cu in 30μl, 0.1M HCl. Incubation temperature (37-90°C) and time (30-120min.) were also investigated. Kits were stored at -10°C and their long term stability was determined as a function of their radiolabeling efficiency. Further, stability of 64Cu-TP3805 complex was evaluated in presence of fetal bovine serum and bovine serum albumin by using SDS polyacrylamide gel electrophoresis. Kits were then used for PET imaging of BC and PC following eIND (101550) and institutional approvals. Specificity of 64Cu-TP3805 for VPAC1 was examined with digital autoradiography (DAR) of prostate tissues obtained after prostatectomy, benign prostatic hyperplasia (BPH) tissue, and benign and malignant lymph nodes. Results were compared with corresponding tissue histology. RESULTS: Radiolabeling efficiency was ≥95% at final pH ~7.2 when incubated at 50°C for 90min. Kits were stable up to 18months when stored at -10°C, and 64Cu-TP3805 complex exhibited excellent stability for up to 4h at room temperature. 64Cu-TP3805 complex did not show any transchelation even after 2h incubation at 37°C in 10% FBS as well as in BSA as determined by SDS PAGE analysis. DAR identified ≥95% of malignant lesions 11 new PC lesions, 20 high grade prostatic intraepithelial neoplasia, 2/2 ejaculatory ducts and 5/5 urethra verumontanum not previously identified The malignant lymph nodes were correctly identified by DAR and for 3/3 BPH patients, and 5/5 cysts, DAR was negative. In human BC (n=19) and PC (n=26) were imaged with 100% sensitivity. CONCLUSION: Availability of ready to use N2S2-peptide kits for 64Cu labeling is convenient and eliminates possible day to day variation during its routine preparation for clinical use.
INTRODUCTION: Previously, our laboratory has shown that 64Cu-TP3805 can specifically target VPAC1 receptors and be used for positron emission tomography (PET) imaging of breast (BC) and prostate cancer (PC) in humans. Present work is aimed at the formulation of a freeze-dried diaminedithiol-peptide (N2S2-TP3805) kit and it's evaluation for the preparation of 64Cu labeled TP3805. Parameters such as pH, temperature and incubation time were examined that influenced the radiolabeling efficiency and stability of the product. METHODS: Kits were prepared under different conditions and radiolabeling efficiency of TP3805 kit was evaluated for a range of pH3.5-8.5, after addition of 64Cu in 30μl, 0.1M HCl. Incubation temperature (37-90°C) and time (30-120min.) were also investigated. Kits were stored at -10°C and their long term stability was determined as a function of their radiolabeling efficiency. Further, stability of 64Cu-TP3805 complex was evaluated in presence of fetal bovine serum and bovineserum albumin by using SDSpolyacrylamide gel electrophoresis. Kits were then used for PET imaging of BC and PC following eIND (101550) and institutional approvals. Specificity of 64Cu-TP3805 for VPAC1 was examined with digital autoradiography (DAR) of prostate tissues obtained after prostatectomy, benign prostatic hyperplasia (BPH) tissue, and benign and malignant lymph nodes. Results were compared with corresponding tissue histology. RESULTS: Radiolabeling efficiency was ≥95% at final pH ~7.2 when incubated at 50°C for 90min. Kits were stable up to 18months when stored at -10°C, and 64Cu-TP3805 complex exhibited excellent stability for up to 4h at room temperature. 64Cu-TP3805 complex did not show any transchelation even after 2h incubation at 37°C in 10% FBS as well as in BSA as determined by SDS PAGE analysis. DAR identified ≥95% of malignant lesions 11 new PC lesions, 20 high grade prostatic intraepithelial neoplasia, 2/2 ejaculatory ducts and 5/5 urethra verumontanum not previously identified The malignant lymph nodes were correctly identified by DAR and for 3/3 BPH patients, and 5/5 cysts, DAR was negative. In human BC (n=19) and PC (n=26) were imaged with 100% sensitivity. CONCLUSION: Availability of ready to use N2S2-peptide kits for 64Cu labeling is convenient and eliminates possible day to day variation during its routine preparation for clinical use.
Authors: Xiaoyan Wang; Robert J Hickey; Linda H Malkas; Michael O Koch; Lang Li; Shaobo Zhang; George E Sandusky; David J Grignon; John N Eble; Liang Cheng Journal: Prostate Date: 2010-10-28 Impact factor: 4.104
Authors: Sarah E Chapman; Justin M Diener; Todd A Sasser; Carlos Correcher; Antonio J González; Tony Van Avermaete; W Matthew Leevy Journal: Am J Nucl Med Mol Imaging Date: 2012-10-15
Authors: Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan Journal: Mol Pharm Date: 2013-01-30 Impact factor: 4.939
Authors: Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057
Authors: Sushil K Tripathi; Rhonda Kean; Emily Bongiorno; Douglas C Hooper; Yuan-Yuan Jin; Eric Wickstrom; Peter A McCue; Mathew L Thakur Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488